Designer epigenome modifiers enable robust and sustained gene silencing in clinically relevant human cells. Issue 9 (10th March 2018)

• Record Type: Journal Article
• Authors: Mlambo, Tafadzwa; Nitsch, Sandra; Hildenbeutel, Markus; Romito, Marianna; Müller, Maximilian; Bossen, Claudia; Diederichs, Sven; Cornu, Tatjana I; Cathomen, Toni; Mussolino, Claudio
• Is Part Of: Nucleic acids research. Volume 46:Issue 9(2018)
• Page Start: 4456
• Page End: 4468
• Publication Date: 2018-03-10
• Subjects: Nucleic acids -- Periodicals; Molecular biology -- Periodicals; 572.805
• DOI: 10.1093/nar/gky171
• Languages: English
• ISSNs: 0305-1048

Abstract

Abstract: Targeted modulation of gene expression represents a valuable approach to understand the mechanisms governing gene regulation. In a therapeutic context, it can be exploited to selectively modify the aberrant expression of a disease-causing gene or to provide the target cells with a new function. Here, we have established a novel platform for achieving precision epigenome editing using designer epigenome modifiers (DEMs). DEMs combine in a single molecule a DNA binding domain based on highly specific transcription activator-like effectors (TALEs) and several effector domains capable of inducing DNA methylation and locally altering the chromatin structure to silence target gene expression. We designed DEMs to target two human genes, CCR5 and CXCR4, with the aim of epigenetically silencing their expression in primary human T lymphocytes. We observed robust and sustained target gene silencing associated with reduced chromatin accessibility, increased promoter methylation at the target sites and undetectable changes in global gene expression. Our results demonstrate that DEMs can be successfully used to silence target gene expression in primary human cells with remarkably high specificity, paving the way for the establishment of a potential new class of therapeutics.